12:00 AM
Sep 27, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TP10: Began Phase I/II testing

Avant Immunotherapeutics Inc. (AVAN), Needham, Mass.
Product: TP10
Business: Cardiovascular
Therapeutic category: Immune modulation
Target: Complement
Description: Soluble form of complement receptor 1...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >